|

NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

RECRUITINGSponsored by Istituto Nazionale di Ricovero e Cura per Anziani
Actively Recruiting
SponsorIstituto Nazionale di Ricovero e Cura per Anziani
Started2022-06-28
Est. completion2025-12-31
Eligibility
Age50 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06317428

Summary

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD patients three months after the iniation of triple inhaled formoterol/glycopyrrolate/budesonide therapy.

Eligibility

Age: 50 Years+Healthy volunteers accepted
Inclusion Criteria:

* COPD;
* Clinical indication for triple inhalation therapy with formoterol/glycopyrrolate/budesonide;

Exclusion Criteria:

* Life expectancy less than one year;

Conditions1

COPD

Browse More Trials

COPD trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.